An example is the dose-escalation/-expansion study phase I/IIa clinical trial, which is evaluating the rationale for the use of the anti-LAG-3 antibody, BMS-986016 and nivolumab in metastatic solid tumours, including the HNSCC cohort (NCT01968109). Here, LAG3 is linked to head and neck squamous cell carcinoma.